Smoking Influence on Apoptosis in Periodontitis

March 15, 2016 updated by: Damascus University

Influence of Smoking on Fibroblast Apoptosis in Patients With Chronic and Aggressive Periodontitis

Apoptosis is an evolutionary form of physiological cell death. Studies suggest that apoptosis is involved in the pathogenesis of periodontal diseases. Human gingival fibroblasts (HGF) have an important role in the periodontal immune response. It is believed that HGF can be diminished and/or eliminated by means of apoptosis.

Smoking is one of the most common risk factor of periodontal disease. Studies indicated that smoking can increase the risk of periodontitis by enhancing the apoptosis of gingival fibroblast.

The purpose of this study is to determine and to investigate apoptosis of HGF in gingival biopsies collected from smokers and non smokers who are diagnosed with chronic periodontitis or aggressive periodontitis.

Eighty subjects will be invited to participate in this study. Patients will be allocated into four groups (20 patients each). Gingival biopsies will be obtained from the base of papillae during surgical treatment (open flap curettage) and will be examined by Immuno-histochemical analysis. Immune-staining will be done using p53 monoclonal mouse anti-human antibody.

Study Overview

Status

Completed

Detailed Description

Background:

The mechanisms responsible for gingival tissue damage are poorly understood, and both immune-mediated reactions and direct cytopathic effects of bacteria maybe involved. Based on direct effect of bacteria in cell cultures, it has been suggested that apoptosis might play an important role in periodontitis (Chen 1994).

Programmed cell death (apoptosis) is normal physiologic process that contributes to maintaining tissue homeostasis. The process of apoptosis can be modulated by various stimuli hormones, cytokines, growth factors, infections and immune-responses (Renehan et al. 2001).

Among other factors, the products of two genes that encode protein p53 and Bcl-2 have been shown to play fundamental regulatory role in apoptosis. P53 is the protein product of tumor-suppressor gene, and expression of P53 can induce apoptosis. This protein is also implicated in the regulation of tissue dynamics, and is specifically thought to induce apoptosis in terminally differentiated cells, including inflammatory cells (Bulut et al.2006).

Fibroblast is a type of cell that synthesizes the extracellular and collagen in connective tissue. It plays a critical role in wound healing. Fibroblasts are the most common cells in connective tissue. The main function of fibroblasts is to maintain the structural integrity of connective tissue by continuously secreting precursors of extracellular matrix. it was reported that apoptosis levels increased in gingivitis and periodontitis (Jarenberg et al. 2002).

Cigarette smoking is a risk factor for many diseases, and recent evidence indicates that smoking adversely influences periodontal health. A number of epidemiologic studies have shown strong association between smoking and prevalence and severity of periodontitis (Bostrom et al. 1998). Whereas, the pathogenesis of periodontitis in smokers is poorly understood there are data suggesting that smoking effects on the periodontal tissues include defects in neutrophil function, impaired serum antibody responses to periodontal pathogens, and potentially diminished gingival fibroblast function (Shivanaikar et al. 2001). Smokers are considered a high-risk group for periodontitis, and smoking history is a useful clinical predictor of future disease activity (Hanokia et al. 2000).

Aims of the study:

  • Investigation of the effects of smoking on fibroblasts apoptosis in smokers with periodontitis compared to non-smokers with periodontitis using immuno-histochemical methods.
  • Comparison of apoptosis levels of gingival fibroblasts between chronic and aggressive periodontitis.

Materials and methods:

A total of 80 subjects will be invited to participate in this study from the patients referred to the Department of Periodontology, Faculty of Dentistry, University of Damascus. The study will be approved by a specific Review Board. Subjects will be recruited according to specific inclusion criteria after completion of medical and dental history questionnaires. Patients will sign a consent form after being advised about the nature of the study.

The selection of patients will be made according of the criteria approved by the 1999 international world workshop for a classification system of periodontal diseases and conditions (Armitage 1999) using five clinical parameters and full mouth or panoramic radiographs for diagnosis.

Subjects will be allocated into four groups:

  • Smoking Chronic Periodontitis group (ChP-S): comprise 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
  • Non-smoking Chronic periodontitis group (ChP-NS): comprise 20 age-sex matched patients who are non-smokers and have chronic periodontitis.
  • Smoking Aggressive Periodontitis group (AgP-S): comprise 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
  • Non-smoking Aggressive periodontitis group (AgP-NS): comprise 20 age- and sex matched patients who are non-smokers and have aggressive periodontitis.

Clinical measurements:

A standard periodontal probe will be used for recording periodontal indices at six sites per tooth. The examined clinical parameters include bleeding on probing (BOP), plaque index (PI), clinical attachment loss (CAL) and periodontal pocket depth (PPD) and gingival index (GI).

Biopsy collection and analysis

  • The biopsy samples will be obtained from patients during surgical treatment (open flap curettage) where biopsy is taken from the base area of papilla.
  • Samples will be placed in 10% formalin.
  • The samples will be then installed in paraffin wax.
  • Samples will be analyzed in the by means of p53 monoclonal mouse anti-human antibody.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Damascus, Syrian Arab Republic, DM20AM18
        • Department of Periodontics, University of Damascus Dental School
      • Damascus, Syrian Arab Republic, DM20AM18
        • Ali Abou Sulaiman

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

A total of 80 subjects will be invited to participate in this study from the patients referred to the Department of Periodontology, Faculty of Dentistry, University of Damascus. Patients should have a diagnosis of periodontitis (either chronic or aggressive). Any candidate will be approached and informed about this clinical study with the relevant information sheet. Informed consent forms will be obtained.Using five clinical parameters and full mouth or panoramic radiographs, the participants will be allocated to four groups according to their condition as well as their smoking habit. The description of these groups has given before.

Description

Inclusion Criteria:

  • Patients of Syrian descent
  • Systemically healthy
  • Have at least 20 teeth

Exclusion criteria:

  • Periodontal treatment during the last three months
  • History of major systemic diseases
  • Consumption of antibiotics or anti-inflammatory drugs in the last three months
  • Smoking
  • Alcohol consumption
  • Pregnant and lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Smoking Aggressive Periodontitis group
This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
Smoking Chronic Periodontitis group
This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
Non-smoking Aggressive Periodontitis grp
This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
Non-smoking Chronic periodontitis grp
This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
P53 levels in gingival biopsy samples
Time Frame: The measurement will be performed at T0 (baseline measurement) once the sample has been recruited
This variable is going to be measured by an immunohistochemical analysis
The measurement will be performed at T0 (baseline measurement) once the sample has been recruited

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
presence or absence of fibroblasts' apoptosis in the gingival tissues
Time Frame: The measurement will be performed at T0 (baseline measurement) once the sample has been recruited
this variable is going to be measured by an immunohistochemical analysis
The measurement will be performed at T0 (baseline measurement) once the sample has been recruited

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ali Abou Sulaiman, DDS MSc PhD, University of Damascus Dental School, Department of Periodontology
  • Study Director: Sharif Barakat, DDS MSc Phd, University of Damascus Dental School, Department of Periodontology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

March 14, 2014

First Submitted That Met QC Criteria

April 7, 2014

First Posted (Estimate)

April 10, 2014

Study Record Updates

Last Update Posted (Estimate)

March 16, 2016

Last Update Submitted That Met QC Criteria

March 15, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aggressive Periodontitis

3
Subscribe